Over the past 12 months, 1 insider at Greenwich LifeSciences, Inc. filed 10 open-market SEC Form 4 transactions on GLSI: 10 purchases worth $536K and 0 sales worth $0. Insiders have been net buyers over this period. The most recent filing was on Jul 24, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 24, 26 | Snehal PatelCEO and CFO, Director, 10% Owner | BUY | 1.1K | $12.88 | $14K |
| Jul 23, 26 | Snehal PatelCEO and CFO, Director, 10% Owner | BUY | 2.5K | $13.14 | $33K |
| Jan 13, 26 | Snehal PatelCEO and CFO | BUY | 1.8K | $29.83 | $54K |
| Jan 12, 26 | Snehal PatelCEO and CFO | BUY | 2.9K | $27.54 | $80K |
| Dec 31, 25 | Snehal PatelCEO and CFO | BUY | 4.3K | $21.36 | $92K |
| Dec 30, 25 | Snehal PatelCEO and CFO | BUY | 2.9K | $21.73 | $63K |
| Dec 18, 25 | Snehal PatelCEO and CFO | BUY | 4.1K | $12.62 | $52K |
| Nov 25, 25 | Snehal PatelCEO and CFO | BUY | 4.6K | $8.37 | $39K |
| Nov 7, 25 | Snehal PatelCEO and CFO | BUY | 10.6K | $8.43 | $89K |
| Oct 31, 25 | Snehal PatelCEO and CFO | BUY | 2.3K | $9.26 | $21K |
| Apr 25, 25 | Snehal PatelCEO and CFO | BUY | 3.6K | $9.88 | $36K |
| Apr 17, 25 | Snehal PatelCEO and CFO | BUY | 5.4K | $8.98 | $48K |
| Apr 7, 25 | Snehal PatelCEO and CFO | BUY | 3.6K | $9.10 | $33K |
| Apr 4, 25 | Snehal PatelCEO and CFO | BUY | 5.5K | $8.73 | $48K |
| Jan 10, 25 | Snehal PatelCEO and CFO | BUY | 2.5K | $12.51 | $31K |
| Jan 7, 25 | Snehal PatelCEO and CFO | BUY | 1.8K | $13.75 | $25K |
| Jan 6, 25 | Snehal PatelCEO and CFO | BUY | 1.1K | $13.31 | $15K |
| Jan 3, 25 | Snehal PatelCEO and CFO | BUY | 3.4K | $12.95 | $44K |
| Jan 2, 25 | Snehal PatelCEO and CFO | BUY | 2.0K | $11.97 | $24K |
| Dec 31, 24 | Snehal PatelCEO and CFO | BUY | 2.4K | $11.36 | $27K |
| Dec 30, 24 | Snehal PatelCEO and CFO | BUY | 3.2K | $11.12 | $36K |
| Nov 21, 24 | Jaye ThompsonVP Clinical Reg Affairs | BUY | 1.0K | $12.91 | $13K |
| Sep 26, 24 | Snehal PatelCEO and CFO | BUY | 1.5K | $14.63 | $22K |
| Aug 12, 24 | Jaye ThompsonVP Clinical Reg Affairs | BUY | 800 | $13.85 | $11K |
| Aug 6, 24 | Snehal PatelCEO and CFO | BUY | 2.0K | $13.81 | $28K |
| Aug 5, 24 | Snehal PatelCEO and CFO | BUY | 5.5K | $13.18 | $72K |
| Aug 2, 24 | Jaye ThompsonVP Clinical Reg Affairs | BUY | 1.0K | $15.15 | $15K |
| Jul 23, 24 | Snehal PatelCEO and CFO | BUY | 1.5K | $15.89 | $24K |
| Jul 18, 24 | Jaye ThompsonVP Clinical Reg Affairs | BUY | 1.0K | $16.00 | $16K |
| Jun 13, 24 | Snehal PatelCEO and CFO | BUY | 174.8K | $14.30 | $2.5M |
| Apr 1, 24 | Snehal PatelCEO and CFO | BUY | 3.0K | $19.08 | $57K |
| Mar 22, 24 | Snehal PatelCEO and CFO | BUY | 2.5K | $19.98 | $50K |
| Mar 20, 24 | Snehal PatelCEO and CFO | BUY | 1.5K | $17.68 | $27K |
| Mar 5, 24 | Snehal PatelCEO and CFO | BUY | 30.5K | $12.49 | $381K |
| Mar 4, 24 | Snehal PatelCEO and CFO | BUY | 4.1K | $13.03 | $53K |
| Feb 16, 24 | Snehal PatelCEO and CFO | BUY | 10.8K | $11.16 | $121K |
| Feb 15, 24 | Snehal PatelCEO and CFO | BUY | 12.7K | $11.07 | $141K |
| Nov 10, 23 | Snehal PatelCEO and CFO | BUY | 5.0K | $10.17 | $51K |
| Nov 3, 23 | Snehal PatelCEO and CFO | BUY | 3.5K | $9.11 | $32K |
| Oct 27, 23 | Jaye ThompsonVP Clinical Reg Affairs | BUY | 500 | $8.57 | $4K |
| Oct 26, 23 | Snehal PatelCEO and CFO | BUY | 2.5K | $7.97 | $20K |
| Oct 25, 23 | Snehal PatelCEO and CFO | BUY | 2.5K | $7.91 | $20K |
| Oct 10, 23 | Snehal PatelCEO and CFO | BUY | 1.0K | $9.07 | $9K |
| Oct 4, 23 | Snehal PatelCEO and CFO | BUY | 2.0K | $8.63 | $17K |
| Sep 26, 23 | Jaye ThompsonVP Clinical Reg Affairs | BUY | 600 | $8.71 | $5K |
| Sep 19, 23 | Snehal PatelCEO and CFO | BUY | 4.0K | $8.95 | $36K |
| Sep 11, 23 | Snehal PatelCEO and CFO | BUY | 1.0K | $9.48 | $9K |
| Aug 22, 23 | Snehal PatelCEO and CFO | BUY | 1.0K | $9.97 | $10K |
| Aug 4, 23 | Snehal PatelCEO and CFO | BUY | 2.0K | $10.55 | $21K |
| Jul 21, 23 | Snehal PatelCEO and CFO | BUY | 1.0K | $9.20 | $9K |
Over the past 12 months, insiders at Greenwich LifeSciences, Inc. filed 10 open-market purchases worth $536K and 0 sales worth $0 on GLSI, which makes them net buyers over the period. The most recent Form 4 was filed on Jul 24, 26.
The largest recent open-market GLSI insider purchase in our data was $2.5M by Snehal Patel, CEO and CFO, filed on Jun 13, 24.
1 different insider at Greenwich LifeSciences, Inc. filed open-market SEC Form 4 transactions on GLSI over the last 12 months.
InsiderTape plots every GLSI insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Greenwich LifeSciences, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →